胆管癌成纤维细胞生长因子受体抑制剂治疗相关白内障
该回顾性病例系列研究纳入18例接受成纤维细胞生长因子受体抑制剂(FGFRi)治疗的FGFR2变异肝内胆管癌患者,9例(50%)在用药后出现白内障或白内障进展,其中5例在停药后确诊;17只白内障眼中8只(47%)需手术。发生白内障者FGFRi治疗时间中位数长于未发生者(13个月 vs 5个月;OR 1.01;95%CI 1.00-1.02;P=.02)。
要点
- 18例接受FGFRi治疗的肝内胆管癌患者中9例(50%)出现白内障或白内障进展。
- 17只白内障眼中8只(47%)需白内障手术,1例因晶状体膨胀性青光眼需急诊手术。
- 发生白内障者FGFRi治疗时间中位数13个月(2-26),未发生者为5个月(1-11)。
核心结论
- 该回顾性病例系列研究因设计所限不能确证因果关系,但结果提示白内障形成或进展是FGFRi治疗的潜在不良反应,支持对接受该治疗的患者考虑定期眼科检查。
研究设计与样本
- 回顾性病例系列研究,数据来自加利福尼亚大学旧金山分校肝胆组织库与登记库中携带FGFR2变异、在临床试验或标准治疗中接受FGFRi的肝内胆管癌患者。
- 数据收集自2015年2月至2021年10月间的患者访视,回顾性调查于2022年9月6日至2023年5月4日进行,数据分析于2023年5月5日至2023年9月6日进行。
- 共纳入18例患者,中位(范围)年龄54(27-81)岁,13例(72%)为女性。
主要发现
- 9例患者(50%)在启动FGFRi后至少1只眼出现白内障或白内障进展。
- 17只白内障眼中8只(47%)需白内障手术;1例患者迅速出现白内障相关晶状体膨胀性青光眼,需急诊手术。
- 从启动FGFRi至白内障发生或恶化的中位(范围)时间约为18(1-23)个月。
- 9例发生白内障或白内障进展的患者中5例(56%)在停用FGFRi后诊断为新发或恶化白内障。
- 发生白内障者FGFRi治疗中位(范围)时长为13个月(2-26),未发生者为5个月(1-11);比值比1.01;95%CI 1.00-1.02;P=.02。
关键数值与推荐
- 主要结局定义为启动FGFRi后新发或恶化白内障。
- 白内障形成与临床协变量的关联采用非配对t检验和Fisher精确检验;使用单一双变量逻辑回归模型检验FGFRi总治疗时长和FGFRi治疗结束时年龄作为白内障发生的预测因素。
临床怎么用
- 作者认为,研究结果支持对接受FGFRi治疗的患者考虑定期眼科检查。
局限性
- 原文述及该回顾性病例系列研究因研究设计所限不能确证因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Since fibroblast growth factor receptor inhibitors (FGFRi) are used for treatment of intrahepatic cholangiocarcinoma (iCCA), understanding potential complications following longer-term use in clinical practice settings is warranted. This study describes cataract formation or progression as a complication of FGFRi use for the treatment of iCCA, even after treatment discontinuation. OBJECTIVE: To describe cases of cataract formation or worsening in patients with iCCA treated with FGFRi and to characterize the ophthalmologic features, risk factors, and outcomes for FGFRi-associated cataracts. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series study used data from patients with iCCA harboring FGFR2 aberrations who received FGFRi in clinical trials or as standard therapy from the University of California, San Francisco, Hepatobiliary Tissue Bank and Registry. Data were collected from patient visits between February 2015 and October 2021, and this retrospective investigation was conducted from September 6, 2022, to May 4, 2023. Data analysis was conducted from May 5, 2023, to September 6, 2023. EXPOSURE: Use of an FGFRi for the treatment of iCCA. MAIN OUTCOMES AND MEASURES: The primary outcome was designated as development of a new or worsening cataract after FGFRi initiation. Statistical analysis for the association between cataract formation and clinical covariates was performed using unpaired t tests and Fisher exact tests. A single bivariate logistic regression model was used to examine total duration of FGFRi therapy and age at the conclusion of FGFRi therapy as predictors of cataract development. RESULTS: A total of 18 patients were included in the study; median (range) patient age was 54 (27-81) years, and 13 patients (72%) were female. Nine patients (50%) developed a cataract or had cataract progression in at least 1 eye after initiation of FGFRi. Of 17 eyes with cataract, 8 eyes (47%) required cataract surgery. One patient rapidly developed a cataract associated with phacomorphic glaucoma, which required urgent surgery. The median (range) time to cataract onset or worsening from initiation of FGFRi was approximately 18 (1-23) months. Five of 9 patients (56%) who developed cataracts or had cataract progression were diagnosed with new or worsening cataracts after discontinuation of FGFRi. Patients who developed cataracts had longer median (range) duration of FGFRi treatment compared with patients who did not develop cataracts (13 months [2-26] vs 5 months [1-11]; odds ratio, 1.01; 95% CI, 1.00-1.02; P = .02). CONCLUSIONS AND RELEVANCE: While this retrospective case series study cannot prove cause and effect conclusively due to the study design, study results highlight cataract formation or progression as a potential adverse effect of FGFRi therapy, supporting consideration of periodic eye examinations in patients who have received this treatment.
引用
- Kassaye I, Alyafaie A, Zhang K, et al. Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma. JAMA Ophthalmol. 2024. PMID: 39446357. doi:10.1001/jamaophthalmol.2024.4395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。